KD Logo

Karyopharm Therapeutics Inc (KPTI) receives an Overweight rating from Piper Sandler

Karyopharm Therapeutics Inc’s filing revealed that its President and CEO Paulson Richard A. unloaded Company’s shares for reported $3172.0 on Oct 04 ’24. In the deal valued at $0.88 per share,3,607 shares were sold. As a result of this transaction, Paulson Richard A. now holds 1,135,607 shares worth roughly $0.97 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, Mano Michael sold 3,971 shares, generating $2,866 in total proceeds. Upon selling the shares at $0.72, the SVP, General Counsel&Secretary now owns 273,881 shares.

Before that, Paulson Richard A. sold 3,667 shares. Karyopharm Therapeutics Inc shares valued at $2,647 were divested by the President and CEO at a price of $0.72 per share. As a result of the transaction, Paulson Richard A. now holds 1,139,214 shares, worth roughly $0.97 million.

Piper Sandler initiated its Karyopharm Therapeutics Inc [KPTI] rating to an Overweight in a research note published on January 19, 2023; the price target was $8. A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who increased its forecast for the stock in early November from “a Sector perform” to “an Outperform”. JP Morgan also remained covering KPTI and has increased its forecast on February 09, 2022 with a “Neutral” recommendation from previously “an Underweight” rating.

Price Performance Review of KPTI

On Tuesday, Karyopharm Therapeutics Inc [NASDAQ:KPTI] saw its stock fall -9.36% to $0.85. Over the last five days, the stock has lost -0.21%. Karyopharm Therapeutics Inc shares have fallen nearly -2.23% since the year began. Nevertheless, the stocks have fallen -4.98% over the past one year. While a 52-week high of $1.95 was reached on 02/06/24, a 52-week low of $0.62 was recorded on 01/16/24. SMA at 50 days reached $0.8052, while 200 days put it at $1.0248.

Levels Of Support And Resistance For KPTI Stock

The 24-hour chart illustrates a support level at 0.8168, which if violated will result in even more drops to 0.7879. On the upside, there is a resistance level at 0.9035. A further resistance level may holdings at 0.9613. The Relative Strength Index (RSI) on the 14-day chart is 49.20, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0240, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 89.66%. Stochastics %K at 25.57% indicates the stock is a holding.

How much short interest is there in Karyopharm Therapeutics Inc?

A steep rise in short interest was recorded in Karyopharm Therapeutics Inc stocks on 2024-10-15, dropping by -0.31 million shares to a total of 17.61 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-13 was 17.93 million shares. There was a decline of -1.78%, which implies that there is a negative sentiment for the stock.

Most Popular